Luiza Gama Coelho Riccio

Luiza Gama Coelho Riccio

Auto-generated profile, based on publicly available information

Luiza Gama Coelho Riccio

Department of Obstetrics, Paulista School of Medicine, Federal University of São Paulo, São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Best Practice & Research Clinical Obstetrics & Gynaecology
Verified
Journal Article
Closed access
LRLuiza da Gama Coelho Riccio
Luiza da Gama Coelho Riccio
PSPietro Santulli
Pietro Santulli
LMLouis Marcellin
Louis Marcellin
MAMauricio Abrao
Mauricio Abrao
FBFrederic Batteux
Frederic Batteux
CCCharles Chapron
Charles Chapron

11 December 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
MJMohamed Jeljeli
Mohamed Jeljeli
LRLuiza Gama Coelho Riccio
Luiza Gama Coelho Riccio
LDLudivine Doridot
Ludivine Doridot
CCCharlotte Chêne
Charlotte Chêne
Carole NiccoCarole Nicco
Carole Nicco
FBFrederic Batteux
Frederic Batteux
Chronic inflammation and fibrosis can result from inappropriately activated immune responses that are mediated by macrophages. Macrophages can acquire memory-like characteristics in response to antigen exposure. Here, we show the effect of BCG or low-dose LPS stimulation on macrophage phenotype, cytokine production, chromatin and metabolic modifications. Low-dose LPS training alleviates fibrosis and inflammation in a mouse model of systemic sclerosis (SSc), whereas BCG-training exacerbates disease in this model. Adoptive transfer of low-dose LPS-trained or BCG-trained macrophages also has beneficial or harmful effects, respectively. Furthermore, coculture with low-dose LPS trained macrophages reduces the fibro-inflammatory profile of fibroblasts from mice and patients with SSc, indicating that trained immunity might be a phenomenon that can be targeted to treat SSc and other autoimmune and inflammatory fibrotic disorders.

1 September 2017 in Journal of Reproductive Immunology
Verified
Journal Article
Closed access
LRL.G.C. Riccio
L.G.C. Riccio
EBEdmund Chada Baracat
Edmund Chada Baracat
CCC. Chapron
C. Chapron
FBFrederic Batteux
Frederic Batteux
MAMauricio Abrao
Mauricio Abrao

1 February 2022 in Journal of Reproductive Immunology
Verified
Journal Article
Closed access
PLPaulo Arantes Laginha
Paulo Arantes Laginha
FAFernanda Vieira Lins Arcoverde
Fernanda Vieira Lins Arcoverde
LRLuiza Gama Coelho Riccio
Luiza Gama Coelho Riccio
MAMarina Paula Andres
Marina Paula Andres
MAMauricio Abrao
Mauricio Abrao

27 June 2019 in Human Reproduction
Verified
Journal Article
Open access
PDF file
LRL G C Riccio
L G C Riccio
MJM Jeljeli
M Jeljeli
PSP Santulli
P Santulli
SCS Chouzenoux
S Chouzenoux
LDL Doridot
L Doridot
FBFrederic Batteux
Frederic Batteux
STUDY QUESTION: What are the effects of B lymphocyte inactivation or depletion on the progression of endometriosis? SUMMARY ANSWER: Skewing activated B cells toward regulatory B cells (Bregs) by Bruton’s tyrosine kinase (Btk) inhibition using Ibrutinib prevents endometriosis progression in mice while B cell depletion using an anti-CD20 antibody has no effect. WHAT IS KNOWN ALREADY: A polyclonal activation of B cells and the presence of anti-endometrial autoantibodies have been described in a large proportion of women with endometriosis though their exact role in the disease mechanisms remains unclear. STUDY DESIGN, SIZE, DURATION: This study included comparison of endometriosis progression for 21 days in control mice versus animals treated with the anti-CD20 depleting antibody or with the Btk inhibitor Ibrutinib that prevents B cell activation. PARTICIPANTS/MATERIALS, SETTING, METHODS: After syngeneic endometrial transplantation, murine endometriotic lesions were compared between treated and control mice using volume, weight, ultrasonography, histology and target genes expression in lesions. Phenotyping of activated and regulatory B cells, T lymphocytes and macrophages was performed by flow cytometry on isolated spleen and peritoneal cells. Cytokines were assayed by ELISA. MAIN RESULTS AND THE ROLE OF CHANCE: Btk inhibitor Ibrutinib prevented lesion growth, reduced mRNA expression of cyclooxygenase-2, alpha smooth muscle actin and type I collagen in the lesions and skewed activated B cells toward Bregs in the spleen and peritoneal cavity of mice with endometriosis. In addition, the number of M2 macrophages decreased in the peritoneal cavity of Ibrutinib-treated mice compared to anti-CD20 and control mice. Depletion of B cells using an anti-CD20 antibody had no effect on activity and growth of endometriotic lesions and neither on the macrophages, compared to control mice. LARGE SCALE DATA: N/A. LIMITATIONS, REASONS FOR CAUTION: It is still unclear whether B cell depletion by the anti-CD20 or inactivation by Ibrutinib can prevent establishment and/or progression of endometriosis in humans. WIDER IMPLICATIONS OF THE FINDINGS: Further investigation may contribute to clarifying the role of B cell subsets in human endometriosis. STUDY FUNDING/COMPETING INTEREST(S): This research was supported by a grant of Institut National de la Santé et de la Recherche Médicale and Paris Descartes University. None of the authors has any conflict of interest to disclose.

6 December 2023 in Reproductive Sciences
Verified
Journal Article
Closed access
PDF file
MAMarina Paula Andres
Marina Paula Andres
LRLuiza Gama Coelho Riccio
Luiza Gama Coelho Riccio
HAHenrique Mendonca Abrao
Henrique Mendonca Abrao
MMMariana Simionato Manzini
Mariana Simionato Manzini
LBLais Braga
Lais Braga
MAMauricio Abrao
Mauricio Abrao